Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03635125 · ClinicalTrials.gov registry record · Phase 4

Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine

A Phase 4 study of JNC 7 Stage 1 or 2 Hypertension, sponsored by Trinity Hypertension & Metabolic Research Institute.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT03635125 is a Phase 4 study of JNC 7 Stage 1 or 2 Hypertension that has completed, run by Trinity Hypertension & Metabolic Research Institute. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03635125, a Phase 4 study of JNC 7 Stage 1 or 2 Hypertension, has completed, sponsored by Trinity Hypertension & Metabolic Research Institute.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an already approved drug, Metoprolol ER with background treatment of Amlodipine.

Interventions

  • DRUG Nebivolol I
  • DRUG Nebivolol II
  • OTHER Baseline Washout Phase

Study Locations (1)

Texas

  • Punzi Medical Center - Carrollton

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2010-08-30
Est. Completion 2011-07-18
Phase Phase 4

What the Registry Record Tells You About NCT03635125

The ClinicalTrials.gov registry entry for NCT03635125 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trinity Hypertension & Metabolic Research Institute, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with JNC 7 Stage 1 or 2 Hypertension appearing as the primary indexed condition, and to 3 interventions - of which Nebivolol I is the first listed.

NCT03635125 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03635125 about?

NCT03635125 is a clinical study titled "Efficacy and Safety of Nebivolol Versus Metoprolol in Hypertensive Subject Taking Amlodipine". Study is to evaluate the effect of Nebivolol to treat high blood pressure compared to an already approved drug, Metoprolol ER with background treatment of Amlodipine.

What is the current status of trial NCT03635125?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2010-08-30. Estimated completion is 2011-07-18.

What conditions does trial NCT03635125 study?

This clinical trial studies the following conditions: JNC 7 Stage 1 or 2 Hypertension.

What interventions are being tested in trial NCT03635125?

The interventions under investigation include: Nebivolol I (DRUG), Nebivolol II (DRUG), Baseline Washout Phase (OTHER).

Who is sponsoring clinical trial NCT03635125?

This trial is sponsored by Trinity Hypertension & Metabolic Research Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03635125 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.